Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Radiotherapy and Oncology 151 (2020) 24–25

Contents lists available at ScienceDirect

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com

COVID-19 Rapid Letter

The importance of IL-6 blockade beyond the COVID-19 pandemic: Consideration for cancer care ☆

The novel human Coronavirus (SARS-CoV-2), which outbroke in Wuhan (China) in late 2019, is now responsible for the pandemic diffusion of COVID-19 [1–3]. Researchers are working on the validation of effective protocols, including antiviral therapies and vaccines [4]. Case-fatality rate seems correlated with virally-driven hyperinflammation [4,5]. In this sense, recent data suggest a crucial role for cytokines release syndrome (CRS) and human interleukin-6 (IL-6) levels as fatality predictors [4,5]. In this regard, tocilizumab, an IL-6 receptor inhibitor, is currently under investigation for patients with severe COVID-19 and elevated IL-6 levels, in order to counteract the pro-inflammatory CRS. Randomized trials have been approved in China and Europe to explore this hypothesis [6,7].

Blocking IL-6 has been proved beneficial in inflammatory diseases, as rheumatoid arthritis [8].

Nevertheless, elevated levels of IL-6 may also play a role in cancer [9].

With respect to cancer pathogenesis, overexpressed IL-6 stimulates the JAK/STAT3 signaling hyperactivation, often associated with poor patients' outcomes [9].

The aberrant hyperactivation of the IL-6/JAK/STAT3 pathway impacts on tumor microenvironment via two mechanisms:

- acting as a driver of tumor cell proliferation and scattering capacity
- suppressing the antitumor immune-response [9].

Specifically, STAT3 hyperactivation has been linked with chemotherapy and radiotherapy (RT) resistance, given its critical role in the interaction between tumor-associated macrophages and tumor cells [10]. Thus, targeting IL-6 may enhance tumor control [9].

The relation between IL-6 and RT has been investigated in head and neck cancer (HNC) [10,11].

Interestingly, in a series of 26 HNC patients, serum levels of pro-inflammatory markers, as IL-6, were found to be increased after RT and chemo-radiotherapy [11]. Thus, paradoxically, cancer treatments may favor a tumor-promoting pro-inflammatory microenvironment [11].

Accordingly, Matsuoka et al. hypothesized improved treatment response and survival in oral squamous cell carcinoma patients, when adding tocilizumab to RT, given its capacity to limit the IL-6 effect in reducing radiation-induced DNA damage [10].

The potential beneficial synergism on tumor microenvironment when combining RT and IL-6 blockade is being currently explored in specific oncological settings, as in pretreated advanced pancreatic cancer (PC) [12]. Patients enrolled within the Danish phase II TRIPPLE-R trial are planned to receive a 15 Gy single fraction of stereotactic body RT (SBRT), nivolumab, ipilimumab and tocilizumab [12].

The rationale is based on preclinical data showing that PC may act via multiple immune-evasion patterns [13].

Therefore, immune-checkpoint inhibitors combination is proposed to overcome the tumor "immune-escape" mechanism to potentially improve outcomes [12]. The addition of tocilizumab is aimed at limiting cancer progression, by counteracting the hyperactivation of the IL-6/JAK/STAT3 pathway [9].

As an immunological adjuvant strategy to increase antigen-release, patients will receive SBRT [12,14].

Of interest, the same 3-drug combination is being evaluated within an ongoing phase II trial enrolling unresectable stage III–IV melanoma patients [15].

To conclude, this pandemic highlighted the importance of the IL-6 pathway within the CRS, observed during severe COVID-19. This led the Scientific Community to focus on the IL-6 blockade clinical potential. Since IL-6 is overexpressed in different cancers, promoting tumor progression, the present times may represent a boost to further investigate the combination of radiotherapy and therapies targeting the IL-6 pathway.

Conflict of interest

No.

Acknowledgement

None.

References

[1] van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382:1564–7.

[2] Jereczek-Fossa BA, Pepa M, Marvaso G, Bruni A, Buglione di Monale E, Bastia M, et al. COVID-19 outbreak and cancer radiotherapy disruption in Italy: survey endorsed by the Italian association of radiotherapy and clinical oncology (AIRO). Radiother Oncol 2020;149:89–93.

☆ The Editors of the Journal, the Publisher and the European Society for Radiotherapy and Oncology (ESTRO) cannot take responsibility for the statements or opinions expressed by the authors of these articles. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. For more information see the editorial "Radiotherapy & Oncology during the COVID-19 pandemic", Vol. 146, 2020.

https://doi.org/10.1016/j.radonc.2020.07.018

[3] Meattini I, Franco P, Belgioia L, Boldrini L, Botticella A, De Santis MC, et al. Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: a view of the nation's young oncologists. ESMO Open 2020;5:e000779.
[4] Metha P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033–4.
[5] Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:846–8.
[6] Chinese Clinical Trial Registry. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). Available at: https://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029765.
[7] A randomized, Double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with COVID-19 pneumonia. ClinicalTrials.gov Identifier: NCT04372186.
[8] Rossi JF, Lu ZY, Michel J, Klein B. Interleukin-6 as a Therapeutic Target. Jean-Francois Rossi. Clin Cancer Res 2015;21:1248–57.
[9] Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 2019;15:234–48.
[10] Matsuoka Y, Nakayama H, Yoshida R, Hirosue A, Nagata M, Tanaka T, et al. IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidant pathway in oral squamous cell carcinoma. Br J Cancer 2016;115:1234–44.
[11] Kiprian D, Czarkowska-Paczek B, Wyczalkowska-Tomasik A, Fuksiewicz M, Kotowicz B, Paczek L. Radiotherapy and radiochemotherapy increase serum levels of pro-inflammatory interleukin-6 and C-reactive protein in patients with head and neck cancers. Transl Cancer Res 2018;7:41–7.
[12] TRIPPLE-R: Phase 2 study in pretreated patients with advanced pancreatic cancer to assess efficacy of ipilimumab, nivolumab and tocilizumab in combination with radiation. ClinicalTrials.gov Identifier: NCT04258150.
[13] Karamitopoulou E. Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. Br J Cancer 2019;121:5–14.
[14] Demaria A, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol 2012;2:153.
[15] A phase II study of the interleukin-6 receptor inhibitor tocilizumab in combination with ipilimumab and nivolumab in patients with unresectable stage III or stage IV melanoma. ClinicalTrials.gov Identifier: NCT03999749.

Giuseppe Carlo Iorio *
Umberto Ricardi
Pierfrancesco Franco
Department of Oncology, Radiation Oncology, University of Turin, Italy
* Corresponding author at: Department of Oncology – Radiation Oncology, University of Turin School of Medicine, Via Genova 3, 10126 Turin, Italy.
E-mail address: giuseppecarlo.iorio@libero.it (G.C. Iorio)
Received 6 June 2020
Received in revised form 6 July 2020

Available online 13 July 2020